US Markets for Stem Cell Therapies 2007

SUMMARY

Though only 2 stem cell products were available in 2007, new stem cell therapy products will begin to enter the market as early as 2009. In the best case scenario, over 30 vendors will enter the stem cell therapy market by 2012, and by 2017, almost 90 vendors will be active in the market.

The US stem cell therapies market includes the use of stem cells to treat orthopedic degenerative disease, cardiovascular disease, diabetes, neurological disease, cancer, retinal disease, aesthetic conditions, and other chronic and autoimmune disorders.

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF EXHIBITS

EXECUTIVE SUMMARY

METHODOLOGY

1.0 STEM CELL THERAPIES BACKGROUND

• 1.1 Regenerative Medicine
• 1.2 Stem Cell Sources, Properties, and Types
  • 1.2.1 Types of Germ Layers
  • 1.2.2 Properties of Stem Cells
  • 1.2.3 Sources and Types of Stem Cells
  • 1.2.4 Approaches to Stem Cell Therapy
  • 1.2.5 Stem Cell Dose
  • 1.2.6 Stem Cell Administration
• 1.3 Stem Cell Challenges
  • 1.3.1 History of Stem Cell Research
  • 1.3.2 Ethical Challenges
  • 1.3.3 Political Challenges
  • 1.3.4 Regulatory Challenges
  • 1.3.5 The Promise of Stem Cell Research
• 1.4 Stem Cell Market

2.0 US STEM CELL THERAPIES MARKET

• 2.1 Market Overview
• 2.2 Market Analysis
  • 2.2.1 Procedures
  • 2.2.2 Market Forecast
  • 2.2.3 Market Drivers and Limiters
    • 2.2.3.1 Market Drivers
    • 2.2.3.2 Market Limiters
• 2.3 Competitive Analysis

3.0 ORTHOPEDIC STEM CELL THERAPY MARKET

• 3.1 Market Overview
  • 3.1.1 Relevant Conditions
  • 3.1.2 Existing Therapies
  • 3.1.3 Stem Cell Therapies
• 3.2 Market Analysis
  • 3.2.1 Procedures
  • 3.2.2 Market Forecast
  • 3.2.3 Market Drivers and Limiters
• 3.3 Competitive Analysis

4.0 CARDIOVASCULAR STEM CELL THERAPY MARKET

• 4.1 Market Overview
  • 4.1.1 Relevant Conditions
  • 4.1.2 Existing Therapies
  • 4.1.3 Stem Cell Therapies
• 4.2 Market Analysis
  • 4.2.1 Procedures
  • 4.2.2 Market Forecast
  • 4.2.3 Market Drivers and Limiters
• 4.3 Competitive Analysis

5.0 DIABETES STEM CELL THERAPY MARKET

• 5.1 Market Overview
  • 5.1.1 Relevant Conditions
  • 5.1.2 Existing Therapies
  • 5.1.3 Stem Cell Therapies
• 5.2 Market Analysis
  • 5.2.1 Procedures
  • 5.2.2 Market Forecast
  • 5.2.3 Market Drivers and Limiters
• 5.3 Competitive Analysis

6.0 NEUROLOGICAL STEM CELL THERAPY MARKET

• 6.1 Market Overview
  • 6.1.1 Relevant Conditions
  • 6.1.2 Existing Therapies
  • 6.1.3 Stem Cell Therapies
• 6.2 Market Analysis
  • 6.2.1 Procedures
  • 6.2.2 Market Forecast
  • 6.2.3 Market Drivers and Limiters
• 6.3 Competitive Analysis

7.0 TISSUE AND ORGAN STEM CELL THERAPY MARKET

• 7.1 Market Overview
  • 7.1.1 Relevant Conditions
  • 7.1.2 Existing Therapies
  • 7.1.3 Stem Cell Therapies
• 7.2 Market Analysis
• 7.3 Competitive Analysis

8.0 COMPANY PROFILES

• 8.1 Aastrom Biosciences
• 8.2 Advanced Cell Technologies
• 8.3 Arteriocyte
• 8.4 Blackstone Medical
• 8.5 Cytori Therapeutics
• 8.6 Geron
• 8.7 Harvest Technologies
• 8.8 International Stem Cell Corporation
• 8.9 Osiris Therapeutics

List of Exhibits

EXECUTIVE SUMMARY

• Exhibit 1: Number of Stem Cell Therapy Products, US, 2007?2017
• Exhibit 2: Number of Orthopedic Stem Cell Therapy Products, US, 2007?2017
• Exhibit 3: Number of Cardiovascular Stem Cell Therapy Products, US, 2007?2017
• Exhibit 4: Number of Diabetes Stem Cell Therapy Products, US, 2007?2017
• Exhibit 5: Number of Neurological Stem Cell Therapy Products, US, 2007?2017
• Exhibit 6: Number of Tissue and Organ Stem Cell Therapy Products, US, 2007?2017

METHODOLOGY

CHAPTER 1: STEM CELL THERAPIES BACKGROUND

• Exhibit 7: The Differentiation Potential of Stem Cells
• Exhibit 8: The Ectoderm, Mesoderm and Endoderm Germ Layers
• Exhibit 9: The Balance of Stem Cell Self